Susan L. Solomon

Solomon speaking in 2016

This article may have been created or edited in return for undisclosed payments. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. (May 2020)

Susan L. Solomon (born 1951) is an American executive. She is the chief executive officer and co-founder of The New York Stem Cell Foundation (NYSCF).^[1]

Early life and family[]

Solomon, the daughter of a pianist and the co-founder of Vanguard Records, grew up in New York City.^[2] She graduated from New York University, and she received her JD from Rutgers University School of Law,^[3] where she was an editor of the Law Review.

She is married to Paul Goldberger, an American architecture critic and educator. They are the parents of three sons and reside in New York City.

Career[]

Solomon started her career as an attorney at Debevoise & Plimpton^[4] and then held executive positions at MacAndrews & Forbes and APAX (formerly MMG Patricof and Co.). She was the founder and President of Sony Worldwide Networks,^[5] the Chairman and CEO of Lancit Media Productions,^{[6][unreliable source?]} an Emmy award-winning television production company, and then served as the founding CEO of Sotheby's website^[7] prior to founding her own strategic management consulting firm Solomon Partners LLC in 2000.

Solomon is a founding Board member of the Global Alliance for iPSC Therapies (GAiT) and New Yorkers for the Advancement of Medical Research (NYAMR). She serves on the Board of the College Diabetes Network^[8] and is an emeritus Board member for the Centre for Commercialization of Regenerative Medicine. She also serves on the Board of Directors of the Regional Plan Association of New York,^[9] where she is a member of the nominating and governance committee. She previously sat on the strategic planning committee for the inaugural NYSTEM program.

Leadership of New York Stem Cell Foundation[]

In 2005, Solomon co-founded The New York Stem Cell Foundation. Solomon started work as a health-care advocate in 1992 when her son was diagnosed with type 1 diabetes.^[10] As a result of her son's diagnosis and then her mother's death from cancer in 2004, she sought to find a way in which the most advanced medical research could translate more quickly into cures. In conversations with clinicians and scientists, Solomon identified stem cells as the most promising way to address unmet patient needs.^[11]

NYSCF is now one of the biggest nonprofits dedicated to stem cell research, employing 45 scientists at their Research Institute in Manhattan and funding an additional 75 scientists around the world.^[12]

Awards[]

• Living Landmark Honoree, New York Landmarks Conservancy, 2015^[13]
• Stem Cell Action Leadership Award, Genetics Policy Institute, 2012^[14]
• New York State Women of Excellence Award 2008^{[15][failed verification]}
• Triumph Award, The Brooke Ellison Foundation, 2008^[16]

Bibliography[]

Publications

• “Institutional Report Cards for Gender Equality: Lessons Learned from Benchmarking Efforts for Women in STEM.” Cell Stem Cell (9 September 2019).
• “Automated, high-throughput derivation, characterization and differentiation of induced pluripotent stem cells.” Nature Methods (3 August 2015).
• “Cell Therapy Worldwide: An Incipient Revolution.” Regenerative Medicine (1 March 2015).
• “7 Actionable Strategies For Advancing Women in Science, Engineering, and Medicine.” Cell Stem Cell (5 March 2015).
• “Human Oocytes Reprogram Adult Somatic Nuclei to Diploid Pluripotent Stem Cells.” Nature (28 April 2014).
• “Twenty years of the International Society for Cellular Therapies: the past, present and future of cellular therapy clinical development.” Cytotherapy (14 April 2014).
• “The New York Stem Cell Foundation. Interview with Susan Solomon.” Regenerative Medicine (November 2012).
• “The New York Stem Cell Foundation: Accelerating Cures Through Stem Cell Research.” Stem Cells Translational Medicine (April 2012).
• “The sixth annual translational stem cell research conference of the New York Stem Cell Foundation.” Annals of the New York Academy of Sciences (May 2012).
• “Private Philanthropy: Freedom From Bureaucracy.” Burrill Stem Cell Report (October 2007): 46–9.
• Case Comment “Monty Python and the Lanham Act: In Search of the Moral Right.” Rutgers Law Review (Winter 1977) 3(2).

Editorials

• “Raising the Standards of Stem Cell Line Quality.” Nature Cell Biology (31 March 2016).
• “Banking on iPSC- Is it Doable and is it Worthwhile.” Stem Cell Research and Reviews (17 December 2014).
• “#StemCells: Education, Innovation, and Outreach.” Cell Stem Cell: Voices (7 November 2013).
• “The New Nonprofit: A Model for Innovation Across Sectors.” Smart Assets: The Philanthropy New York Blog (14 March 2013).
• “Stem Cell Research: Science, Not Politics.” The Huffington Post (21 September 2010).
• “Opinion: Science Shoved Aside in Stem Cell Ruling.” AOL News (25 August 2010).
• “Opportunity for Excellence: The Critical Role of State Programs in the New Federal Landscape.” The Huffington Post (12 June 2009).
• “Patients Before Politics: Putting Science First.” The Huffington Post (9 March 2009).
• “The Stem Cell Wars Are Not Over.” The Huffington Post (30 November 2007).
• “After Bush’s Veto, What is Next for Stem Cell Research?” The Huffington Post (20 June 2007).
• “Spitzer Shows Leadership in Stem Cell Research.” Times Union (18 February 2007).
• “Today’s Stem Cell Bill: A Politically Expedient Approach.” The Huffington Post (18 July 2006).

References[]